Cloudbreak Pharma Inc. (02592) disclosed that on 30 October 2025, it issued 3,888,018 new ordinary shares, accounting for approximately 0.46% of the previous total of 840,677,874 shares. The newly issued shares were allotted under its Series C Equity Incentive Arrangement, with an issue price of HKD 0.

Following this issuance, the total number of issued shares increased to 844,565,892 as of 30 October 2025. The board confirmed that the transaction met relevant listing rules and compliance requirements, and no share repurchases or redemptions were reported for this period.